VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | Outcomes of complement inhibition with eculizumab in adult TA-TMA

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses the results of an analysis aiming to compare strategies and outcomes of patients with transplant-associated thrombotic microangiopathy (TA-TMA) treated with eculizumab. At a median follow-up of 11.1 months, overall survival was found to be significantly higher in patients that received eculizumab, suggesting benefit for complement inhibition in this patient population. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter